Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications.

Anticoagulant medications are used widely for a variety of medical and surgical diseases, disorders, and conditions associated with thrombosis and thromboembolism. This review highlights labeled indications, mechanisms of action, potential drug interactions, and specific pharmacokinetic characteristics of available anticoagulants as an essential foundation for guiding selection and management of therapies for patients undergoing neurosurgical procedures.

• Publication year

  2018

• Venue

  Neurosurgery clinics of North America

• Publication date

  2018-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.nec.2018.06.003PMID 30223963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Betrixaban (PRT054021): pharmacology, dose selection and clinical studies.

  2014cited by this paper
• The pharmacology of novel oral anticoagulants

  2013cited by this paper
• Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

  2012cited by this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans

  2012cited by this paper
• Preclinical experimental models of drug metabolism and disposition in drug discovery and development

  2012cited by this paper
• Factor Xa and thrombin as targets for new oral anticoagulants.

  2011cited by this paper
• Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

  2011cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

  2009cited by this paper
• Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

  2008cited by this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Pharmacokinetics and dosage adjustment in patients with renal dysfunction

  2008cited by this paper
• Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.

  2006cited by this paper
• Direct thrombin inhibitors: pharmacology and clinical relevance

  2005cited by this paper
• Thrombin formation.

  2003cited by this paper
• Fondaparinux: a new antithrombotic agent.

  2002cited by this paper
• Bivalirudin: a direct thrombin inhibitor.

  2002cited by this paper
• The Gut as a Barrier to Drug Absorption

  2001cited by this paper
• Low-molecular-weight heparins.

  1997cited by this paper
• Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

  1997cited by this paper
• Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

  1995cited by this paper
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

  1995cited by this paper
• Warfarin-induced changes in procoagulant and anticoagulant proteins.

  1995cited by this paper
• The Effect of the Synthetic Pentasaccharide SR 90107/ORG 31540 on Thrombin Generation Ex Vivo Is Uniquely due to ATIII-Mediated Neutralization of Factor Xa

  1995cited by this paper
• Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans

  1993cited by this paper
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

  1992cited by this paper
• Oral anticoagulant drugs.

  1991cited by this paper
• The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.

  1988cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Warfarin

  1986cited by this paper
• Applied biopharmaceutics and pharmacokinetics

  1980cited by this paper
• L OW -M OLECULAR -W EIGHT H EPARINS

  year unknowncited by this paper

• An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.

  2026cites this paper
• Design and Evaluation of β-Cyclodextrin-Modified Warfarin-Chitosan and Warfarin-Silica Composites for Controlled Drug Release: In Vitro and in Vivo Approach

  2026cites this paper
• Transforming Emergency Care: An In-Depth Review of the Latest Advances in Emergency Medications

  2026cites this paper
• Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion.

  2025cites this paper
• Preventable deaths related to haemorrhage in England and Wales, 2013-2022: A systematic case series of coroners' reports.

  2025cites this paper
• A Deep Overview of Anticoagulant Drugs: Recent Synthesis and Their Activity Assay

  2024cites this paper
• Unfractionated Heparin Administered Every 8 h Outperforms 12 Hourly Administration for Venous Thromboembolism Prophylaxis in Reconstructive Head and Neck Tumor Patients: A 12 Year Retrospective Cohort Study

  2024cites this paper
• [Hemostatic disorders in neurosurgical patients: diagnostics and correction].

  2023cites this paper
• Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information

  2023influential citation
• Anticoagulant Macromolecules

  2023cites this paper
• Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus

  2023cites this paper
• The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants

  2022cites this paper
• Management of Patients undergoing Elective Craniotomy under Antiplatelet or Anticoagulation Therapy: An International Survey of Practice

  2022cites this paper
• The Effect of Anticoagulation on the Treatment of Dupuytren Contracture with Collagenase

  2022cites this paper
• Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting

  2022cites this paper
• Coagulation factors XI and XII as possible targets for anticoagulant therapy.

  2022cites this paper
• Comparison of the Mortality and Bleeding Risk of Anticoagulant Doses in COVID-19 Patients: A Systematic Review and Meta-analysis

  2022cites this paper
• Recent Advancements in Oral Anticoagulants: A Systematic Review

  2022cites this paper
• Anticoagulant use to treat VTE (venous thromboembolism) in pregnancy: a review

  2022cites this paper
• Planning neurosurgical interventions in patients with anticoagulant therapy

  2022cites this paper
• Role of Inferior Vena Cava Filter Retrieval in Patients on Chronic Anticoagulation Therapy

  2021cites this paper
• Potential Drug-Drug Interactions in Patients Using Warfarin, Heparin, and Enoxaparin

  2021cites this paper
• Simulation of anticoagulation in atrial fibrillation patients with rivaroxaban-from trial to target population.

  2021cites this paper
• Licania rigida Benth leaf extracts: Assessment of toxicity and potential anticoagulant effect

  2021cites this paper
• Rationalizing post‐operative prophylactic anticoagulation in reconstructive head and neck cancer patients: a review

  2021cites this paper
• Chronic subdural haematoma in antithrombotic cohorts: characteristics, surgical outcomes, and recurrence

  2020cites this paper
• Exploitation of Fibrinolytic Enzymes in Combating Blood Clotting Disorders – Recent Advances and Strategies: A Comprehensive Review

  2020cites this paper
• Practice of stereoelectroencephalography (sEEG) in drug-resistant epilepsy: retrospective series with surgery and thermocoagulation outcomes.

  2020cites this paper